Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

Ankara University

Status: Completed

Conditions: Coronary Artery Disease; Metabolic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02054390

ACEmetsend

Details and patient eligibility

About

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Enrollment: 459 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. metabolic syndrome
2. elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion criteria

1. acute coronary events
2. renal failure
3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
4. left main coronary artery disease
5. chronic total occlusion
6. high levels of baseline CKMB or troponin
7. any contraindication of aspirin, clopidogrel or ACEi treatment